10
MNiSW
71.22
ICV
REVIEW PAPER
 
CC BY-NC-ND 3.0
 
 

Hypertension – The Silent Killer

Katarzyna Sawicka 1, 2  ,  
Marek Prasał 2,  
 
1
Chair of Internal Medicine and Department of Internal Medicine in Nursing, Medical University, Lublin, Poland
2
Department of Cardiology, Medical University, Lublin, Poland
JPCCR 2011;5(2):43–46
KEYWORDS:
ABSTRACT:
Hypertension is often called ‘the silent killer’ because it shows no early symptoms and, simultaneously, is the single most significant risk factor for atherosclerosis and all clinical manifestations of atherosclerosis. It is an independent predisposing factor for heart failure, coronary artery disease, stroke, renal disease, and peripheral arterial disease. It is the most important risk factor for cardiovascular morbidity and mortality in industrialized countries.
CORRESPONDING AUTHOR:
Katarzyna Sawicka   
Chair of Internal Medicine and Department of Internal Medicine in Nursing, Medical University, Lublin, Jaczewskiego 8, 20-954 Lublin, Poland.
 
REFERENCES (33):
1. Mancia G, Grassi G, Kjeldsen SE. Nadciśnienie tętnicze – podręcznik European Society of Hypertension, VIA MEDICA, Gdańsk 2009.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365(9455):217-223.
3. Mancia G, De Backer G, Dominiczak A, Cifk ova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HAJ, Zanchetti A. 2007 Guidelines for the management of arterial of hypertension. Th e Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
4. Carretero OA, Oparil S. Essential hypertension. Part I: defi nition and etiology. Circulation 2000;101(3):329-335.
5. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann NY Acad Sci 2006;1083:77-110.
6. Lackland DT, Egan BM. Dietary salt restriction and blood pressure in clinical trials. Curr Hypertens Rep 2007;9(4):314-319.
7. Pitts SR, Adams RP. Emergency department hypertension and regression to the mean. Ann Emerg Med 1998;31(2):214-218.
8. De Leeuw PW, Kroon AA. Hypertension and the Development of Heart Failure. J Cardiovasc Pharmacol 1998;32(Suppl 1):9-15.
9. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study. Am J Cardiol 1971;27:335-346.
10. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV. Remodeling and reparation of the cardiovascular system. An international perspective. J Am Coll Cardiol 1992;20:3-16.
11. Houghton JL, Frank MJ, Carr AA, Von Dohlen JW, Prisant LM. Relations among impaired coronary fl ow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990;15:43- 51.
12. Dunn FG, Pringle SD. Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens 1993;11:1003-1010.
13. Fouad-Tarazi FM. Left ventricular diastolic dysfunction in hypertension. Curr Opin Cardiol 1994;9:551-560.
14. Verma A, Solomon SD. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am 2009; 93(3):647-664.
15. Lenihan DJ, Gerson MC, Dorn GW II, Hoit BD, Walsh RA. Eff ects of changes in atrioventricular gradient and contractility on left ventricular fi lling in human diastolic cardiac dysfunction. Am Heart J 1996;132:1179-1188.
16. Fukuta H, Little WC. Diagnosis of diastolic heart failure. Curr Cardiol Rep 2007;9(3):224-228.
17. Schwartzkopff B, Motz W, Vogt M, Strauer BE. Heart failure on the basis of hypertension. Circulation 1993;87(Suppl IV):66-72.
18. Cuspidi C, Sala C, Zanchetti A. Management of hypertension in patients with left ventricular hypertrophy. Curr Hypertens Rep 2007;9(6):498- 505.
19. Ross R: Th e pathogenesis of atherosclerosis – an update. New Engl J Med 1986;14:488-500.
20. Tso MO, Jampol LM. Pathophysiology of hypertensive retinopathy. Ophthalmology 1982; 89(10):1132-1145.
21. Walsh JB. Hypertensive retinopathy. Description, classifi cation, and prognosis. Ophthalmology 1982;89(10):1127-1131.
22. Wong TY, Mitchell P. Hypertensive retinopathy. New Engl J Med 2004;351(22):2310–2317.
23. Palm F, Urbanek C, Grau A. Infection, its treatment and the risk of stroke. Curr Vasc Pharmacol 2009;7(2):146-152.
24. Lawes C, Bennett D, Feigin V, Rodgers A. Blood pressure and stroke. An overview of published reviews. Stroke 2004; 35:1024-1033.
25. Sare GM, Geeganage C, Bath PM. High blood pressure in acute ischemic stroke--broadening therapeutic horizons. Cerebrovasc Dis 2009;27(Suppl 1):156-161.
26. Moretti R, Torre P, Antonello RM, Manganaro D, Vilotti C, Pizzolato G. Risk factors for vascular dementia: hypotension as a key point. Vasc Health Risk Manag 2008;4(2):395-402.
27. Birns J, Kalra L. Cognitive function and hypertension. J Hum Hyperten 2009;23(2):86-96.
28. Isles CG. Management of hypertensive crises. Scott Med J 1995;40(1): 23-25.
29. O’Hara McCoy H. Posterior reversible encephalopathy syndrome: an emerging clinical entity in adult, pediatric, and obstetric critical care. J Am Acad Nurse Pract 2008;20(2):100-106.
30. Khosla N, Kalaitzidis R, Bakris GL. Th e kidney, hypertension, and remaining challenges. Med Clin N Am 2009;93(3):697-715.
31. Krzesiński JM, Cohen EP. Hypertension and the kidney. Acta Clin Belg 2007;62(1):5-14.
32. Palmer BF. Hypertension management in patients with chronic kidney disease. Curr Hypertens Rep 2008;10(5):367-373.
33. Ono H, Ono Y. Nephrosclerosis and hypertension. Med Clin N Am 1997;81(6):1273-1288.
eISSN:1898-7516
ISSN:1898-2395